Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men

Diabetes Care

Volumn 30, Issue 6, 2007, Pages 1574-1576

  Yaturu, Subhashini ^a,b   Bryant, Barbara ^a   Jain, Sushil K ^b  

^a OVERTON BROOKS VA MEDICAL CENTER   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; ROSIGLITAZONE;

ADVERSE OUTCOME; AGED; ARTICLE; BODY MASS; BONE DENSITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; SIDE EFFECT; TREATMENT RESPONSE;

BONE DENSITY; BONE RESORPTION; DIABETES MELLITUS, TYPE 2; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 34249905512     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2606     Document Type: Article

References (22)

1. Meyer HE, Tverdal A, Falch JA: Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol 137:1203-1211, 1993
2. Forsen L, Meyer HE, Midthjell K, Edna TH: Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 42:920-925, 1999
3. Michaelsson K, Holmberg L, Mallmin H, Sorensen S, Wolk A, Bergstrom R, Ljunghall S: Diet and hip fracture risk: a case-control study: study group of the Multiple Risk Survey on Swedish Women for Eating Assessment. Int J Epidemiol 24:771-782, 1995
4. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM: Risk factors for hip fracture in white women: study of Osteoporotic Fractures Research Group. N Engl J Med 332:767-773, 1995
5. Schwartz AV, Hillier TA, Sellmeyer DE, Resnick HE, Gregg E, Ensrud KE, Schreiner PJ, Margolis KL, Cauley JA, Nevitt MC, Black DM, Cummings SR: Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 25:1749-1754, 2002
6. Wallace C, Reiber GE, LeMaster J, Smith DG, Sullivan K, Hayes S, Vath C: Incidence of falls, risk factors for falls, and fall-related fractures in individuals with diabetes and a prior foot ulcer. Diabetes Care 25:1983-1986, 2002
7. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ: Diabetes and risk of fracture: the Blue Mountains Eye Study. Diabetes Care 24:1198-1203, 2001
8. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR: Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32-38, 2001
9. Gregg EW, Mangione CM, Cauley JA, Thompson TJ, Schwartz AV, Ensrud KE, Nevitt MC: Diabetes and incidence of functional disability in older women. Diabetes Care 25:61-67, 2002
10. Ryerson B, Tierney EF, Thompson TJ, Engelgau MM, Wang J, Gregg EW, Geiss LS: Excess physical limitations among adults with diabetes in the U.S. population, 1997-1999. Diabetes Care 26:206-210, 2003
11. Gregg EW, Beckles GL, Williamson DF, Leveille SG, Langlois JA, Engelgau MM, Narayan KM: Diabetes and physical disability among older U.S. adults. Diabetes Care 23:1272-1277, 2000
12. Nicodemus KK, Folsom AR: Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192-1197, 2001
13. Strotmeyer ES, Cauley JA, Schwartz AV, de Rekeneire N, Resnick HE, Zmuda JM, Shorr RI, Tylavsky FA, Vinik AI, Harris TB, Newman AB: Reduced peripheral nerve function is related to lower hip BMD and calcaneal QUS in older white and black adults: the Health, Aging, and Body Composition Study. J Bone Miner Res 21:1803-1810, 2006
14. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406, 2004
15. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC: Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203-216, 2004
16. Sottile V, Seuwen K, Kneissel M: Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75:329-337, 2004
17. Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M: Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 69:46-50, 2001
18. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147, 1999
19. Beresford JN: Osteogenic stem cells and the stromal system of bone and marrow. Clin Orthop Relat Res 270-280, 1989
20. Bennett JH, Joyner CJ, Triffitt JT, Owen ME: Adipocytic cells cultured from marrow have osteogenic potential. J Cell Sci 99:131-139, 1991
21. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 351:1106-1118, 2004
22. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL: Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 74:357-371, 1999